Results 271 to 280 of about 207,642 (318)
Correction to "Enhanced Clearance of HIV-1 Broadly Neutralizing Antibody VRC07-523-LS During Viremia: Influences on Trial Design and Analysis". [PDF]
europepmc +1 more source
Structural basis for a potent human neutralizing antibody targeting a conserved epitope on the H7 hemagglutinin head. [PDF]
Li J +14 more
europepmc +1 more source
Hantavirus Gn<sup>H</sup> Nanoparticle Immunogen Elicits a Cross-Neutralizing Antibody Response in Mice. [PDF]
Ramos KE +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Broadly Neutralizing Antiviral Antibodies
Annual Review of Immunology, 2013A fascinating aspect of viral evolution relates to the ability of viruses to escape the adaptive immune response. The widely held view has been that the great variability of viral glycoproteins would be an absolute obstacle to the development of antibody-based therapies or vaccines that could confer broad and long-lasting protection.
Corti D., Lanzavecchia A.
openaire +3 more sources
Production of Neutralizing Antibody
2018Techniques employing monoclonal antibodies (mAbs) are widely used in the initial development phase of biologics. The usefulness of mAbs in basic RA research has been established based on their characteristics, including specificity of binding, homogeneity, and ability to be produced on a large scale.
Erika, Takemasa +2 more
openaire +2 more sources
Neutralization of HIV by Antibodies
2008Antibodies can neutralize HIV-1 with potency and cross-reactivity that varies widely and is related but not correlated to their antigen-binding affinity. Therefore, in addition to measuring binding affinity, an evaluation of the antibody neutralizing activity in tissue cultures is important for development of antibody-based therapeutics, design of ...
Ilia, Prado +2 more
openaire +2 more sources
Protective neutralizing antibodies
Science, 2020Coronavirus Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Rogers et al.
openaire +1 more source

